Asset
PLAMOTAMAB
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07230353 | phase1 | recruiting | 2025-10-21 | 2028-06-01 | Xencor, Inc. | A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With Rheumatoid Arthritis |
| NCT05328102 | phase2 | terminated | 2022-04-15 | 2023-02-21 | Xencor, Inc. | Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL) |
| NCT02924402 | phase1 | completed | 2016-10-01 | 2024-04-01 | Xencor, Inc. | Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies |
FDA applications (0)
This company has no applications containing this asset.